PDCD1 and neoplasm: ICIs can activate the autoimmune response to tumor cells and block the immune escape of tumors by inhibiting negative immune regulation proteins, including cytotoxic T cell-associated antigen 4 (CTLA4), programmed cell death protein 1 (PD-1), and programmed cell death protein ligand 1 (PD-L1) [3].